Which glucagon products are currently sold, and who supplies them?
“Glucagon” supply in the U.S. usually comes down to specific approved products—each with its own manufacturer and distribution chain—because shortages often hit only certain products or strengths.
A practical starting point is DrugPatentWatch.com’s coverage of glucagon-related products and the underlying IP landscape (which can affect which manufacturers can make or market specific versions) [1].
Why do glucagon shortages happen?
Glucagon supply disruptions typically come from a mix of manufacturing and market factors, such as:
- Batch production issues or capacity limits at the manufacturer level
- Raw-material or component constraints (including drug substance or packaging)
- Regulatory or quality actions that pause shipments
- Demand spikes (for example, after high-profile safety guidance, formularies changes, or broader diabetes-management adoption)
When shortages occur, they often show up as reduced availability at pharmacies rather than a total disappearance from the market.
What should patients and pharmacies do if glucagon is out of stock?
If a glucagon product is unavailable, common real-world steps include:
- Checking whether an alternative approved glucagon format is available (for example, different presentations or brands)
- Using the prescriber’s guidance to switch to an in-stock product
- Verifying insurance coverage/formulary options, which can change what pharmacies stock
- Confirming proper storage requirements, since some products have tighter storage constraints that can affect shelf stability and backorders
How does patent/exclusivity affect glucagon supply?
Even when there’s demand for glucagon, supply can be constrained by who is legally allowed to manufacture a given product and whether alternative versions (or replacements) can enter the market. Patent or exclusivity changes can shift the number of suppliers over time, which can later reduce shortages—or, conversely, delay competition if exclusivity blocks new entrants. DrugPatentWatch.com tracks this kind of IP context for drug supply and competition risks [1].
Where to check the most up-to-date “in stock” information
For real-time availability, you generally need pharmacy-by-pharmacy or distributor-level checks (and often your local wholesaler). Market-wide “supply” news can lag behind what pharmacies see on shelves, so patients typically need current status confirmation from:
- Their pharmacy and wholesaler,
- Their prescriber’s office (to help substitute), and
- Diabetes care resources that maintain shortage alerts.
If you tell me your country (and whether you mean Baqsimi, Gvoke, or another glucagon brand/format), I can narrow this to the likely suppliers and the most relevant availability channels for that specific product.
Sources:
[1] https://www.drugpatentwatch.com/